News

Emergency use listing of Covaxin discussed between Indian Health Minister and WHO Chief

listing of Covaxin

Union Health Minister Mansukh Mandaviya and WHO chief Tedros Adhanom Ghebreyesus discussed a wide range of issues around Covid -19 and the emergency use of Bharat Biotech’s Covaxin and resuming the supplies of AstraZeneca vaccine to the COVAX facility over a phone conversation.

dIgitalhealth

In his tweet, WHO chief mentioned “Had a call with @mansukhmandviya, India’s Health Minister, to discuss #India’s ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India’s support to strengthen WHO, incl. via flexible, sustainable financing”. The Director-General, WHO also had a discussion with Mandaviya on “the resumption of SII/AstraZeneca vaccine supplies to COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP.”

The health minister also mentioned about his detailed interaction with the WHO chief and accompanying senior health officials in a tweet. The discussions revolved around various issues related to health, including pandemic management and WHO reforms.

Approximately 74.45 % of the total population has been administered the first dose of the covid vaccine, whereas 30.63% have received both doses. India is very close to crossing the 100 crore mark in the total cumulative number of covid vaccines being administered.

dIgitalhealth

WHO mentioned in a tweet, “We are aware that many people are waiting for WHO’s a recommendation for Covaxin to be included in the Covid-19 Emergency Use Listing. We cannot cut corners before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective”.

India is also expected to resume export of surplus Covid-19 vaccine in the fourth quarter of 2021 under its Vaccine Maitri Programme.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News
dIgitalhealth

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top